Volume 2, Number 4—October 1996
Synopsis
New Vaccines for the Prevention of Pneumococcal Infections
Helena Käyhty
and Juhani Eskola
and Juhani EskolaTable 2
Antibody response of Finnish infants to pneumococcal conjugate vaccines administered at 2, 4, and 6 months of age*.
| Geometric Mean of the Anti-PNC PS (mg/ml) |
|||||||||
| Type 6B |
Type 14 |
Type 19F |
Type 23F |
||||||
| Vaccine |
Pre |
Post |
Pre |
Post |
Pre |
Post |
Pre |
Post |
Ref. |
| PncOMPC | 0.17 | 1.30 | 0.42 | 8.27 | 0.34 | 9.85 | 0.28 | 1.90 | (50) |
| PncCRM | 0.25 | 0.50 | 0.30 | 2.49 | 0.46 | 1.13 | 0.18 | 0.83 | (52) |
| PncT01-4 | 0.25 | 0.89 | 0.24 | 2.84 | 0.36 | 3.73 | 0.18 | 0.82 | (56) |
| PncT01-8 | 0.20 | 1.28 | 0.30 | 2.56 | 0.56 | 4.23 | 0.22 | 1.03 | (29) |
| PncD03-4 | 0.26 | 0.88 | 0.44 | 2.20 | 0.43 | 5.29 | 0.21 | 0.67 | (56) |
| PncD03-8 |
0.17 |
1.44 |
0.31 |
4.62 |
0.37 |
4.94 |
0.24 |
1.07 |
(29) |
| PncOMP = tetravalent conjugate vaccine with a meningococcal outer membrane protein complex as a carrier PncCRM = pentavalent oligosaccharide conjugate vaccine with CRM197 protein as a carrier PncT01-4 = tetravalent conjugate vaccine with tetanus toxoid carrier; 1 mg of each of four polysaccharides PncT01-8 = tetravalent conjugate vaccine with tetanus toxoid carrier; 1 mg of each of four polysaccharides PncD03-4 = tetravalent conjugate vaccine with diphtheria toxoid carrier; 3mg of each of four polysaccharides PncD03-8 = octavalent conjugate vaccine with diphtheria toxoid carrier; 3mg of each of four polysaccharides *Serum samples are taken before immunization (pre) and at 7 months (post). The data have been gathered from separate studies done in the same population. | |||||||||
